142 related articles for article (PubMed ID: 15570704)
1. [Prostate cancer. Epidemiology. Risk factors. Pathology].
Fournier G; Valeri A; Mangin P; Cussenot O
Ann Urol (Paris); 2004 Oct; 38(5):187-206. PubMed ID: 15570704
[TBL] [Abstract][Full Text] [Related]
2. [Prostate cancer. Treatment].
Fournier G; Valeri A; Mangin P; Cussenot O
Ann Urol (Paris); 2004 Oct; 38(5):225-58. PubMed ID: 15570706
[TBL] [Abstract][Full Text] [Related]
3. Molecular pathology of prostate cancer.
Konishi N; Shimada K; Ishida E; Nakamura M
Pathol Int; 2005 Sep; 55(9):531-9. PubMed ID: 16143027
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic regulators in prostatic intraepithelial neoplasia (PIN): value in prostate cancer detection and prevention.
Zeng L; Kyprianou N
Prostate Cancer Prostatic Dis; 2005; 8(1):7-13. PubMed ID: 15477876
[TBL] [Abstract][Full Text] [Related]
5. [Epidemiological fundamentals of clinically localized prostate cancer].
Martínez-Salamanca JI; Ballesteros CM; Carballido Rodríguez J
Arch Esp Urol; 2011 Oct; 64(8):703-10. PubMed ID: 22052753
[TBL] [Abstract][Full Text] [Related]
6. [Epidemiologic indicators of adenocarcinoma of the prostate. Results on 436 patients].
Arrizabalaga Moreno M; García González JI; Diez Rodríguez JM; Esteban Artiaga R; Castro Pita M; Navarro Sebastian J; Mora Durbán M; Paniagua Andrés P
Actas Urol Esp; 1997 Oct; 21(9):852-61. PubMed ID: 9471868
[TBL] [Abstract][Full Text] [Related]
7. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Bostwick DG; Pacelli A; Blute M; Roche P; Murphy GP
Cancer; 1998 Jun; 82(11):2256-61. PubMed ID: 9610707
[TBL] [Abstract][Full Text] [Related]
8. The role of P501S and PSA in the diagnosis of metastatic adenocarcinoma of the prostate.
Sheridan T; Herawi M; Epstein JI; Illei PB
Am J Surg Pathol; 2007 Sep; 31(9):1351-5. PubMed ID: 17721190
[TBL] [Abstract][Full Text] [Related]
9. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database.
Bandini M; Mazzone E; Preisser F; Nazzani S; Zaffuto E; Marchioni M; Tian Z; Pompe RS; Tilki D; Graefen M; Shariat SF; Montorsi F; Saad F; Briganti A; Karakiewicz P
Eur Urol Oncol; 2018 Sep; 1(4):314-320. PubMed ID: 31100253
[TBL] [Abstract][Full Text] [Related]
10. [Relation of serum prostate-specific antigen and the Gleason grade in patients with prostatic carcinoma].
Zivković S; Velicković L; Kostov M; Stojanović N
Vojnosanit Pregl; 2003; 60(4):449-54. PubMed ID: 12958804
[TBL] [Abstract][Full Text] [Related]
11. [Prostate cancer: Diagnosis and staging].
Fournier G; Valeri A; Mangin P; Cussenot O
Ann Urol (Paris); 2004 Oct; 38(5):207-24. PubMed ID: 15570705
[TBL] [Abstract][Full Text] [Related]
12. Detection of subclinical cancers by prostate-specific antigen screening in asymptomatic men from high-risk prostate cancer families.
Matikainen MP; Schleutker J; Mörsky P; Kallioniemi OP; Tammela TL
Clin Cancer Res; 1999 Jun; 5(6):1275-9. PubMed ID: 10389909
[TBL] [Abstract][Full Text] [Related]
13. Genetic epidemiology of prostate cancer.
Narod S
Biochim Biophys Acta; 1999 Jan; 1423(1):F1-13. PubMed ID: 9989206
[TBL] [Abstract][Full Text] [Related]
14. Prostatic intraepithelial neoplasia is a risk factor for adenocarcinoma: predictive accuracy in needle biopsies.
Davidson D; Bostwick DG; Qian J; Wollan PC; Oesterling JE; Rudders RA; Siroky M; Stilmant M
J Urol; 1995 Oct; 154(4):1295-9. PubMed ID: 7544835
[TBL] [Abstract][Full Text] [Related]
15. Prostate carcinoma among men with human immunodeficiency virus infection.
Crum NF; Spencer CR; Amling CL
Cancer; 2004 Jul; 101(2):294-9. PubMed ID: 15241826
[TBL] [Abstract][Full Text] [Related]
16. Correlation between immunohistochemical patterns and serum levels of PSA and PSAP in prostatic pathology: evaluation of 198 prostatic fine needle biopsies.
Vitali A; Ardoino S; Durante P; Ferro MA; Li Causi F; Parodi C; Sanguineti G; Gaffuri M; Paerachino M; Salvadori RP
Anticancer Res; 1994; 14(4A):1503-7. PubMed ID: 7526771
[TBL] [Abstract][Full Text] [Related]
17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
18. Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): an open-label, randomised, phase 3 factorial trial.
Denham JW; Joseph D; Lamb DS; Spry NA; Duchesne G; Matthews J; Atkinson C; Tai KH; Christie D; Kenny L; Turner S; Gogna NK; Diamond T; Delahunt B; Oldmeadow C; Attia J; Steigler A
Lancet Oncol; 2014 Sep; 15(10):1076-89. PubMed ID: 25130995
[TBL] [Abstract][Full Text] [Related]
19. [Evolution and prognostic factors of adenocarcinomas of the prostate metastasizing at diagnosis].
Arrizabalaga Moreno M; García González JI; Mora Durvan M; Díez Rodríguez JM; Esteban Artiaga R; Navarro Sebastián J; Castro Pita M; Paniagua Andrés P
Actas Urol Esp; 1997 Sep; 21(8):724-36. PubMed ID: 9412221
[TBL] [Abstract][Full Text] [Related]
20. Clinical, haemodynamic, anthropometric, metabolic and insulin profile of men with high-stage and high-grade clinical prostate cancer.
Hammarsten J; Högstedt B
Blood Press; 2004; 13(1):47-55. PubMed ID: 15083641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
